So, this study has been conducted as a basic pharmacoeconomic simulatory analysis to assess the cost escalation and risk reduction, with additional safety, which would be expected if SGLT-2 and DPP-IV inhibitors were hypothetically substituted as add-on drugs in prescriptions of T2DM patients with ASCVD, HF, and/or CKD or those who are clinically judged to be at high risk for the same due to presence of multiple risk factors. This evidence concerns the gene SLC5A2 and hydrops fetalis.